多西他赛联合卡培他滨治疗复发转移性乳腺癌的临床疗效观察

Clinical Effect of Docetaxel Combined with Capecitabine on Treatment of Metastatic Breast Cancer

目的观察多西他赛联合卡培他滨治复发转移性乳腺癌的近期临床疗效及其不良反应。方法 32例复发转移性乳腺癌患者应用多西他赛75mg/m2静滴,第1d;卡培他滨1200mg/m2口服,2次/d,第1~14d。21d为1个周期,至少2周期后评价近期临床疗效和不良反应。结果所有患者中CR2例（6.3%）,PR15例（46.9%）,SD10例（31.3%）,PD5例（15.6%）;RR为53.1%,CBR为84.4%。不良反应主要为恶心与呕吐、粒细胞减少、手足综合征,多为Ⅰ~Ⅱ度。结论卡培他滨联合多西他赛治疗复发转移性乳腺癌临床疗效确切,不良反应可以耐受,可以作为晚期乳腺癌有效的治疗方案。

Objective To observe the clinical effect of docetaxel combined with capecitabine on treatment of metastatic breast cancer and its toxicity.Methods 32 patients with metastatic breast cancer were given docetaxel 75mg/m2 intravenously,d1 and capecitabine 1200mg/m2 orally,twice a day,d1-14.21d was regarded as a cycle.The short-term clinical effect and toxicity were evaluated at least after two cycles.Results Among all the patients,2 cases were CR（6.3%）,15 cases were PR（46.9%）,10 cases SD were（31.3%） and 5 cases were PD（15.6%）.The RR was 53.1% and the CBR was 84.4%.The most toxicity was nausea and vomiting,neutropenia and hand-foot syndrome,mostly Ⅰ-Ⅱ degree.Conclusion Docetaxel combined with capecitabine is an effective regimen for patients with metastatic breast cancer and the toxicity can be tolerated.